PMID- 26758058
OWN - NLM
STAT- MEDLINE
DCOM- 20160822
LR  - 20220316
IS  - 1432-2307 (Electronic)
IS  - 0945-6317 (Linking)
VI  - 468
IP  - 4
DP  - 2016 Apr
TI  - A significant subgroup of resectable gallbladder cancer patients has an HER2 
      positive status.
PG  - 431-9
LID - 10.1007/s00428-015-1898-1 [doi]
AB  - Gallbladder cancer (GBC) has a poor prognosis, and new targeted therapeutic 
      options are needed. We investigated the human epidermal growth factor receptor 2 
      (HER2) status and its clinicopathological significance in a large cohort of GBC 
      patients. We assessed HER2 expression in a consecutive series of 211 GBC cases by 
      immunohistochemistry (IHC), paying particular attention to intratumoral 
      heterogeneity. HER2 gene amplification was analyzed by dual-color fluorescence in 
      situ hybridization (FISH). An HER2 positive status was called when the IHC score 
      was 3+ or when the IHC score was 2+, and FISH was positive. Correlations were 
      analyzed between HER2 status and clinicopathological parameters including 
      survival. The HER2 IHC score was 0 in 144 (68.2%), 1+ in 28 (13.3%), 2+ in 14 
      (6.6%), and 3+ in 25 cases (11.8%). In 20/39 (51%) of the IHC 2+ and 3+ cases, 
      the staining pattern was heterogeneous. In HER2 IHC score 2+ and 3+ cases, HER2 
      FISH was positive in 83% (10/12) and 96% (24/25), respectively. Altogether, 
      35/211 cases (16.6%) were HER2 positive. There was no significant association 
      between HER2 status and clinicopathological variables or survival. We identified 
      a significant subgroup of HER2-positive GBC cases, for whom a clinical trial with 
      anti-HER2 therapy might be considered.
FAU - Yoshida, Hiroshi
AU  - Yoshida H
AD  - Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, 
      5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Shimada, Kazuaki
AU  - Shimada K
AD  - Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 
      5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Kosuge, Tomoo
AU  - Kosuge T
AD  - Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 
      5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Hiraoka, Nobuyoshi
AU  - Hiraoka N
AD  - Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, 
      5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. nhiraoka@ncc.go.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160113
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma/*genetics/pathology
MH  - Female
MH  - Gallbladder Neoplasms/*genetics/pathology
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/analysis/*biosynthesis
OTO - NOTNLM
OT  - Fluorescence in situ hybridization
OT  - Gallbladder cancer
OT  - HER2
OT  - Heterogeneity
OT  - Immunohistochemistry
EDAT- 2016/01/14 06:00
MHDA- 2016/08/23 06:00
CRDT- 2016/01/14 06:00
PHST- 2015/06/08 00:00 [received]
PHST- 2015/12/28 00:00 [accepted]
PHST- 2015/10/24 00:00 [revised]
PHST- 2016/01/14 06:00 [entrez]
PHST- 2016/01/14 06:00 [pubmed]
PHST- 2016/08/23 06:00 [medline]
AID - 10.1007/s00428-015-1898-1 [pii]
AID - 10.1007/s00428-015-1898-1 [doi]
PST - ppublish
SO  - Virchows Arch. 2016 Apr;468(4):431-9. doi: 10.1007/s00428-015-1898-1. Epub 2016 
      Jan 13.